John Libbey Eurotext

European Journal of Dermatology


Chilblains observed during the COVID-19 pandemic cannot be distinguished from classic, cold-related chilblains Volume 32, numéro 3, May-June 2022

  • [1.] Cappel MA, Cappel JA, Wetter DA. Pernio (Chilblains), SARS-CoV-2 and COVID toes unified through cutaneous and systemic mechanisms. Mayo Clin Proc 2021; 96: 989-1005.
  • [2.] Freeman EE, McMahon DE, Fox LP. Emerging evidence of the direct association between COVID-19 and chilblains. JAMA Dermatol 2021; 157: 238-9.
  • [3.] Balestri R, Magnano M, Rizzoli L, Rech G. Do we have serological evidences that chilblain-like lesions are related to SARS-CoV-2? A review of the literature. Dermatol Ther 2020; 33: e14229.
  • [4.] Sánchez-García V, Hernández-Quiles R, de-Miguel-Balsa E, Docampo-Simón A, Belinchón-Romero I, Ramos-Rincón JM. Are the chilblain-like lesions observed during the COVID-19 pandemic due to severe acute respiratory syndrome coronavirus 2? Systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2022; 36: 24-38.
  • [5.] Colmenero I, Santonja C, Alonso-Riaño M, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol 2020; 183: 729-37.
  • [6.] Recalcati S, Barbagallo T, Tonolo S, Milani M, Fantini F. Relapse of chilblain-like lesions during the second wave of coronavirus disease 19. J Eur Acad Dermatol Venereol 2021; 35: e315-6.
  • [7.] Lipsker D. A chilblain epidemic during the COVID-19 pandemic. A sign of natural resistance to SARS-CoV-2? Med Hypotheses 2020; 144: 109959.
  • [8.] Hubiche T, Cardot-Leccia N, Le Duff F, et al. Clinical, laboratory, and interferon-alpha response characteristics of patients with chilblain-like lesions during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 202-6.
  • [9.] Damsky W, Peterson D, King B. When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection. J Am Acad Dermatol 2020; 83: e269-70.
  • [10.] Battesti G, El Khalifa J, Abdelhedi N, et al. New insights in COVID-19-associated chilblains: a comparative study with chilblain lupus erythematosus. J Am Acad Dermatol 2020; 83: 1219-22.
  • [11.] Aschoff R, Zimmermann N, Beissert S, Günther C. Type I interferon signature in chilblain-like lesions associated with the COVID-19 pandemic. Dermatopathology (Basel) 2020; 7: 57-63.
  • [12.] Bessis D. Impaired type I interferon response in SARS-CoV-2 infection: looking through the cutaneous window. Br J Dermatol 2021; 184: 11-2.
  • [13.] Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020; 370: eabd4585.
  • [14.] Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020; 370: eabd4570.
  • [15.] Santonja C, Heras F, Núñez L, Requena L. COVID-19 chilblainlike lesion: immunohistochemical demonstration of SARS-CoV-2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction-negative patient. Br J Dermatol 2020; 183: 778-80.
  • [16.] Magro CM, Mulvey JJ, Laurence J, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol 2021; 184: 141-50.
  • [17.] Baeck M, Hoton D, Marot L, Herman A. Chilblains and COVID-19: why SARS-CoV-2 endothelial infection is questioned. Br J Dermatol 2020; 183: 1152-3.
  • [18.] von Stillfried S, Boor P. Nachweismethoden von SARS-CoV-2 in Gewebe [Methods of SARS-CoV-2 detection in tissue]. Pathologe 2021; 42: 208-15.
  • [19.] Herman A, Peeters C, Verroken A, et al. Evaluation of chilblains as a manifestation of the COVID-19 Pandemic. JAMA Dermatol 2020; 156: 998-1003.
  • [20.] Data from Sciensano, the Belgian institute for health responsible for the epidemiological follow-up of the COVID-19 epidemic (
  • [21.] Fischer B, Lindenkamp C, Lichtenberg C, Birschmann I, Knabbe C, Hendig D. Evidence of long-lasting humoral and cellular immunity against SARS-CoV-2 even in elderly COVID-19 convalescents showing a mild to moderate disease progression. Life (Basel) 2021; 11: 805.
  • [22.] Vono M, Huttner A, Lemeille S, et al. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. Cell Rep 2021; 37: 109773.
  • [23.] Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631-7.
  • [24.] Potdar AA, Dube S, Naito T, et al. Altered intestinal ACE2 levels are associated with inflammation, severe disease and response to anti-cytokine therapy in inflammatory bowel disease. Gastroenterology 2021; 160: 809-22.e7.
  • [25.] Verstockt B, Verstockt S, Abdu Rahiman S, et al. Intestinal receptor of SARS-CoV-2 in inflamed IBD tissue seems downregulated by HNF4A in ileum and upregulated by interferon regulating factors in colon. J Crohns Colitis 2021; 15: 485-98.
  • [26.] Freeman EE, McMahon DE, Hruza GJ, et al. Timing of PCR and antibody testing in patients with COVID-19-associated dermatologic manifestations. J Am Acad Dermatol 2021; 84: 505-7.
  • [27.] Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. J Exp Med 2016; 213: 2527-38.
  • [28.] Papa R, Volpi S, Gattorno M. Monogenetic causes of chilblains, panniculitis and vasculopathy: the Type I interferonopathies. G Ital Dermatol Venereol 2020; 155: 590-8.
  • [29.] Nyssen A, Benhadou F, Magnée M, André J, Koopmansch C, Wautrecht JC. Chilblains. Vasa 2020; 49: 133-40.
  • [30.] Roca-Ginés J, Torres-Navarro I, Sánchez-Arráez J, et al. Assessment of acute acral lesions in a case series of children and adolescents during the COVID-19 pandemic. JAMA Dermatol 2020; 156: 992-7.
  • [31.] Neri I, Virdi A, Corsini I, et al. Major cluster of paediatric ’true’ primary chilblains during the COVID-19 pandemic: a consequence of lifestyle changes due to lockdown. J Eur Acad Dermatol Venereol 2020; 34: 2630-5.
  • [32.] Rouanet J, Lang E, Beltzung F, et al. Recent outbreak of chilblainlike lesions is not directly related to SARS-CoV-2 infection. J Eur Acad Dermatol Venereol 2020; 34: e689-92.
  • [33.] Kluger N. Why are chilblains underreported in Nordic countries during the COVID-19 pandemic? An analysis of Google Trends. J Eur Acad Dermatol Venereol 2021; 35: e100-1.
  • [34.] McCleskey PE, Zimmerman B, Lieberman A, et al. Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic. JAMA Dermatol 2021; 157: 947-53.